IDH1
Also known as: IDH1 R132H
Use
IDH1 mutations are frequent genetic alterations in low‑grade diffuse gliomas and secondary glioblastoma (approximately 70%), and are less common (<10%) in primary glioblastoma. Immunohistochemistry (IHC) for IDH1 R132H is used as a diagnostic tool to assess mutation status and help differentiate primary GBM from other glioma subtypes.
Special Instructions
Not provided.
Limitations
Not provided.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
IDH1
Protein
Result Turnaround Time
24 hours
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
FFPE tissue block is preferred; alternatively, one unbaked unstained H&E slide (required) plus two to three positively charged unstained slides (4‑5 microns) per test/antibody.
Storage Instructions
Use cold pack for transport; cold pack must not contact specimen directly. NYS clients to provide date and time of collection.